Page 135 - Read Online

Ibrahim et al ALDHs and prostate cancer

76. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study 2011;71:2561-71.
of androgen receptors in metastatic prostate cancer. Comparison 93. Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR,
of receptor content and response to hormonal therapy. Cancer Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, Ng SW.
1991;67:3057-64. Characterization of aldehyde dehydrogenase isozymes in ovarian
77. Feldman BJ, Feldman D. The development of androgen-independent cancer tissues and sphere cultures. BMC Cancer 2012;12:329.
prostate cancer. Nat Rev Cancer 2001;1:34-45. 94. Giacalone NJ, Den RB, Eisenberg R, Chen H, Olson SJ, Massion
78. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting PP, Carbone DP, Lu B. ALDH7A1 expression is associated with
the androgen receptor: improving outcomes for castration-resistant recurrence in patients with surgically resected non-small-cell lung
prostate cancer. Endocr Relat Cancer 2004;11:459-76. carcinoma. Future Oncol 2013;9:737-45.
79. Scher HI, Sawyers CL. Biology of progressive, castration-resistant 95. Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello
prostate cancer: directed therapies targeting the androgen-receptor C, Bruzzese F, Carriero MV, Budillon A. Proteomic analysis of
signaling axis. J Clin Oncol 2005;23:8253-61. zoledronic-acid resistant prostate cancer cells unveils novel pathways
80. Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald characterizing an invasive phenotype. Oncotarget 2015;6:5324-41.
W, Scher HI. Persistent prostate-specific antigen expression after 96. Chandran UR, Ma CQ, Dhir R, Bisceglia M, Lyons-Weiler M, Liang
neoadjuvant androgen depletion: an early predictor of relapse or WJ, Michalopoulos G, Becich M, Monzon FA. Gene expression
incomplete androgen suppression. Urology 2006;68:834-9. profiles of prostate cancer reveal involvement of multiple molecular
81. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the pathways in the metastatic process. BMC Cancer 2007;7:64.
androgen receptor to prostate cancer predisposition and progression. 97. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M,
Cancer Metastasis Rev 2001;20:207-23. Brooks JD, Pollack JR. The retinoic acid synthesis gene ALDH1a2
82. Steinkamp MP, O’Mahony OA, Brogley M, Rehman H, Lapensee is a candidate tumor suppressor in prostate cancer. Cancer Res
EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin 2005;65:8118-24.
MA, Pienta KJ, Robins DM. Treatment-dependent androgen receptor 98. Touma SE, Perner S, Rubin MA, Nanus DM, Gudas LJ. Retinoid
mutations in prostate cancer exploit multiple mechanisms to evade metabolism and ALDH1A2 (RALDH2) expression are altered in
therapy. Cancer Res 2009;69:4434-42. the transgenic adenocarcinoma mouse prostate model. Biochem
83. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood Pharmacol 2009;78:1127-38.
CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase 99. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar
by intratumoral de novo steroidogenesis during progression of N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL,
castration-resistant prostate cancer. Cancer Res 2008;68:6407-15. Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay
84. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: JW, Gazdar AF, Minna JD. A genome-wide screen for promoter
a diversity of functions converging on and regulating the AR methylation in lung cancer identifies novel methylation markers for
transcriptional complex. Endocr Rev 2007;28:778-808. multiple malignancies. PLoS Med 2006;3:e486.
85. Zhu ML, Kyprianou N. Androgen receptor and growth factor 100. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective
signaling cross-talk in prostate cancer cells. Endocr Relat Cancer identification of tumorigenic prostate cancer stem cells. Cancer Res
2008;15:841-9. 2005;65:10946-51.
86. Bergerat JP, Ceraline J. Pleiotropic functional properties of androgen 101. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA,
receptor mutants in prostate cancer. Hum Mutat 2009;30:145-57. George NJ, Clarke NW. Characterization of benign and malignant
87. Duan JJ, Cai J, Guo YF, Bian XW, Yu SC. ALDH1A3, a metabolic prostate epithelial Hoechst 33342 side populations. Prostate
target for cancer diagnosis and therapy. Int J Cancer 2016;139:965-75. 2007;67:1384-96.
88. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger 102. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.
RCM, van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells
is functionally involved in prostate cancer bone metastasis. Clin Exp that provide a model for patients with poor prognosis. Br J Cancer
Metastasis 2011;28:615-25. 2008;98:756-65.
89. Brocker C, Lassen N, Estey T, Pappa A, Cantore M, Orlova VV, 103. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification
Chavakis T, Kavanagh KL, Oppermann U, Vasiliou V. Aldehyde of a cell of origin for human prostate cancer. Science 2010;329:568-71.
dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved 104. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC,
in cellular defense against hyperosmotic stress. J Biol Chem Li HF, Cheng AJ. Head and neck cancer in the betel quid chewing
2010;285:18452-63. area: recent advances in molecular carcinogenesis. Cancer Sci
90. Yang Z, Yang X, Wu Y, Wang J, Zhang Y, Xiong H, Jiang Y, Qin 2008;99:1507-14.
J. Clinical diagnosis, treatment, and ALDH7A1 mutations in 105. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-
pyridoxine-dependent epilepsy in three Chinese infants. PLoS One initiating stem-like cells in human prostate cancer exhibit increased
2014;9:e92803. NF-kappaB signalling. Nat Commun 2011;2:162.
91. Scharer G, Brocker C, Vasiliou V, Creadon-Swindell G, Gallagher 106. Maitland NJ, Frame FM, Polson ES, Lewis JL, Collins AT. Prostate
RC, Spector E, Van Hove JL. The genotypic and phenotypic spectrum cancer stem cells: do they have a basal or luminal phenotype? Horm
of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. J Cancer 2011;2:47-61.
Inherit Metab Dis 2010;33:571-81. 107. Maitland NJ, Collins AT. Cancer stem cells - a therapeutic target?
92. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Curr Opin Mol Ther 2010;12:662-73.
Vega YSdMEC, Medicherla R, Christos PJ, Shapiro R, Pavlick 108. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM,
A, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT,
Osman I. Integrative genomics identifies molecular alterations that Donahoe PK. Ovarian cancer side population defines cells with
challenge the linear model of melanoma progression. Cancer Res stem cell-like characteristics and Mullerian inhibiting substance

Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ Aug 21, 2018 13